v3.25.4
License and Collaboration Revenue and Other Funding Agreements, Viatris License Agreement (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Nov. 06, 2022
USD ($)
Nov. 30, 2022
USD ($)
Dec. 31, 2025
USD ($)
Performanceobligation
Dec. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Contract Assets and Unbilled Receivables [Abstract]          
Revenue recognized     $ 14,196 $ 10,992  
Viatris License Agreement [Member]          
Collaboration and License Agreement [Abstract]          
Viatris license and cost sharing agreement $ 50,000        
Non-refundable cash payment received   $ 35,000      
Maximum amount of payments receivable for development, regulatory and commercial milestones 130,000        
First milestone payments received $ 10,000        
Maximum percentage of tiered royalties receivable     20.00%    
Number of distinct performance obligations | Performanceobligation     2    
Non-cancellation period of Constraint for Research and Development Revenue     120 days    
Contract Assets and Unbilled Receivables [Abstract]          
Balance as of beginning of period     $ 2,209 1,407  
Revenue recognized     14,196 10,992  
Balance as of end of period     1,170 2,209  
Viatris License Agreement [Member] | License Transfer Fee [Member]          
Contract Assets and Unbilled Receivables [Abstract]          
Reclassification to accounts receivable related to costs billed under the Viatris License Agreement     (15,235) $ (10,190)  
Viatris License Agreement [Member] | Sales Milestones [Member]          
Collaboration and License Agreement [Abstract]          
Milestone payment requirements attributed to the FDA's approval         $ 10,000
Contract Assets and Unbilled Receivables [Abstract]          
Revenue recognized     $ 0